Clinical Trial Update: Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression [Phase 1]

View source ↗

Summary

A Phase 1 feasibility study of fondaparinux (Arixtra) in chemotherapy-pretreated ovarian cancer patients at high risk of progression has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ARIXTRA (fondaparinux sodium)

Snippet

Sponsor: NYU Langone Health | Conditions: Ovarian Carcinoma | Phase 1 | Status: WITHDRAWN